-
Something wrong with this record ?
Immunization with WT1-derived peptides by tattooing inhibits the growth of TRAMP-C2 prostate tumor in mice
Katerina Babiarova, Luda Kutinova, Kamila Zurkova, Jitka Krystofova, Eva Brabcova, Petr Hainz, Jan Musil, Sarka Nemeckova
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NS10660
MZ0
CEP Register
- MeSH
- Adjuvants, Immunologic MeSH
- Azacitidine analogs & derivatives pharmacology therapeutic use MeSH
- Injections, Intradermal MeSH
- Antibodies, Monoclonal immunology MeSH
- Mice, Inbred BALB C MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Prostatic Neoplasms therapy MeSH
- Poly I-C pharmacology therapeutic use MeSH
- WT1 Proteins administration & dosage immunology MeSH
- Antineoplastic Agents pharmacology therapeutic use MeSH
- Cancer Vaccines administration & dosage MeSH
- Vaccines, Subunit administration & dosage MeSH
- Tattooing MeSH
- Transforming Growth Factor beta antagonists & inhibitors immunology MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The expression of the transcription factor encoded by the Wilms tumor gene 1 (WT1) is associated with a variety of human cancers. WT1 protein has been reported to serve as a target antigen for tumor-specific immune responses. We observed that the immunization of mice with peptide vaccines derived from WT1 in a mixture with the CpG adjuvant (ODN 1826) by tattoo administration was superior to subcutaneous delivery of the peptides in combination with CpG formulated with the mineral oil adjuvant or a DNA vaccine or a recombinant vaccinia virus vaccine expressing the truncated WT1 protein. Tattooing with the WT1122-140 and WT1126-134 peptide elicited the response of WT1-specific interferon-γ-producing T cells. Peptide vaccine administered with a tattoo device had an antitumor effect on the growth of the prostate tumor cell line TRAMP-C2, provided that the transforming growth factor-β produced by tumor cells was neutralized by anti-TGFβ monoclonal antibody. The treatment of the tumor-bearing mice with 5-azadeoxycytidine or poly IC did not work in synergy with the peptide vaccine.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13000695
- 003
- CZ-PrNML
- 005
- 20170509084633.0
- 007
- ta
- 008
- 130108s2012 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/cji.0b013e3182618381 $2 doi
- 035 __
- $a (PubMed)22735806
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Babiarová, Katarína $u Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague 2, Czech Republic. $7 xx0118496
- 245 10
- $a Immunization with WT1-derived peptides by tattooing inhibits the growth of TRAMP-C2 prostate tumor in mice / $c Katerina Babiarova, Luda Kutinova, Kamila Zurkova, Jitka Krystofova, Eva Brabcova, Petr Hainz, Jan Musil, Sarka Nemeckova
- 520 9_
- $a The expression of the transcription factor encoded by the Wilms tumor gene 1 (WT1) is associated with a variety of human cancers. WT1 protein has been reported to serve as a target antigen for tumor-specific immune responses. We observed that the immunization of mice with peptide vaccines derived from WT1 in a mixture with the CpG adjuvant (ODN 1826) by tattoo administration was superior to subcutaneous delivery of the peptides in combination with CpG formulated with the mineral oil adjuvant or a DNA vaccine or a recombinant vaccinia virus vaccine expressing the truncated WT1 protein. Tattooing with the WT1122-140 and WT1126-134 peptide elicited the response of WT1-specific interferon-γ-producing T cells. Peptide vaccine administered with a tattoo device had an antitumor effect on the growth of the prostate tumor cell line TRAMP-C2, provided that the transforming growth factor-β produced by tumor cells was neutralized by anti-TGFβ monoclonal antibody. The treatment of the tumor-bearing mice with 5-azadeoxycytidine or poly IC did not work in synergy with the peptide vaccine.
- 650 _2
- $a adjuvancia imunologická $7 D000276
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a monoklonální protilátky $x imunologie $7 D000911
- 650 _2
- $a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
- 650 _2
- $a azacytidin $x analogy a deriváty $x farmakologie $x terapeutické užití $7 D001374
- 650 _2
- $a protinádorové vakcíny $x aplikace a dávkování $7 D019496
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a injekce intradermální $7 D007271
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední BALB C $7 D008807
- 650 _2
- $a poly I-C $x farmakologie $x terapeutické užití $7 D011070
- 650 _2
- $a nádory prostaty $x terapie $7 D011471
- 650 _2
- $a tetování $7 D013653
- 650 _2
- $a transformující růstový faktor beta $x antagonisté a inhibitory $x imunologie $7 D016212
- 650 _2
- $a subjednotkové vakcíny $x aplikace a dávkování $7 D022223
- 650 _2
- $a proteiny WT1 $x aplikace a dávkování $x imunologie $7 D025721
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kutinova, Luda
- 700 1_
- $a Zurkova, Kamila
- 700 1_
- $a Krystofova, Jitka
- 700 1_
- $a Brabcová, Eva $7 xx0212445
- 700 1_
- $a Hainz, Petr
- 700 1_
- $a Musil, Jan $7 xx0210384
- 700 1_
- $a Nemeckova, Sarka
- 773 0_
- $w MED00181508 $t Journal of immunotherapy (Hagerstown, Md. 1997) $x 1537-4513 $g Roč. 35, č. 6 (2012), s. 478-487
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22735806 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130108 $b ABA008
- 991 __
- $a 20170509085008 $b ABA008
- 999 __
- $a ok $b bmc $g 963477 $s 798859
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 35 $c 6 $d 478-487 $i 1537-4513 $m Journal of immunotherapy $n J Immunother $x MED00181508
- GRA __
- $a NS10660 $p MZ0
- LZP __
- $a Pubmed-20130108